[go: up one dir, main page]

FR2861991B1 - Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose - Google Patents

Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose

Info

Publication number
FR2861991B1
FR2861991B1 FR0313134A FR0313134A FR2861991B1 FR 2861991 B1 FR2861991 B1 FR 2861991B1 FR 0313134 A FR0313134 A FR 0313134A FR 0313134 A FR0313134 A FR 0313134A FR 2861991 B1 FR2861991 B1 FR 2861991B1
Authority
FR
France
Prior art keywords
glucosidase inhibitors
mucoviscidose
therapy
gen
delf508
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0313134A
Other languages
English (en)
Other versions
FR2861991A1 (fr
Inventor
Frederic Becq
Caroline Norez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0313134A priority Critical patent/FR2861991B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Poitiers filed Critical Centre National de la Recherche Scientifique CNRS
Priority to SI200431106T priority patent/SI1680105T1/sl
Priority to CA2545133A priority patent/CA2545133C/fr
Priority to BRPI0416228-5A priority patent/BRPI0416228A/pt
Priority to DE602004019674T priority patent/DE602004019674D1/de
Priority to DK04805405T priority patent/DK1680105T3/da
Priority to AU2004289083A priority patent/AU2004289083B2/en
Priority to AT04805405T priority patent/ATE423561T1/de
Priority to RU2006119914/14A priority patent/RU2358725C2/ru
Priority to NZ547261A priority patent/NZ547261A/en
Priority to JP2006538890A priority patent/JP4740868B2/ja
Priority to US10/578,328 priority patent/US7973054B2/en
Priority to ZA200603726A priority patent/ZA200603726B/en
Priority to KR1020107004147A priority patent/KR20100038452A/ko
Priority to KR1020067010948A priority patent/KR100979276B1/ko
Priority to HR20090159T priority patent/HRP20090159T1/xx
Priority to CNB2004800382212A priority patent/CN100534432C/zh
Priority to PT04805405T priority patent/PT1680105E/pt
Priority to ES04805405T priority patent/ES2321725T3/es
Priority to PL04805405T priority patent/PL1680105T3/pl
Priority to EP04805405A priority patent/EP1680105B1/fr
Priority to PCT/FR2004/002858 priority patent/WO2005046672A2/fr
Publication of FR2861991A1 publication Critical patent/FR2861991A1/fr
Priority to IL175453A priority patent/IL175453A/en
Priority to NO20062617A priority patent/NO336904B1/no
Application granted granted Critical
Publication of FR2861991B1 publication Critical patent/FR2861991B1/fr
Priority to CY20091100518T priority patent/CY1110468T1/el
Priority to US13/116,482 priority patent/US8242136B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR0313134A 2003-11-07 2003-11-07 Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose Expired - Fee Related FR2861991B1 (fr)

Priority Applications (26)

Application Number Priority Date Filing Date Title
FR0313134A FR2861991B1 (fr) 2003-11-07 2003-11-07 Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
HR20090159T HRP20090159T1 (en) 2003-11-07 2004-11-05 Use of glucosidase inhibitors for therapy of mucovisidosis
BRPI0416228-5A BRPI0416228A (pt) 2003-11-07 2004-11-05 uso de inibidores glucosidade para terapia de mucovisidose
DE602004019674T DE602004019674D1 (de) 2003-11-07 2004-11-05 Verwendung von glucosidase-hemmern zur behandlung von mukoviszidose
DK04805405T DK1680105T3 (da) 2003-11-07 2004-11-05 Anvendelse af en glukosidaseinhibitorer til behandling af mucoviscidose
AU2004289083A AU2004289083B2 (en) 2003-11-07 2004-11-05 Use of glucosidase inhibitors for therapy of mucovisidosis
AT04805405T ATE423561T1 (de) 2003-11-07 2004-11-05 Verwendung von glucosidase-hemmern zur behandlung von mukoviszidose
RU2006119914/14A RU2358725C2 (ru) 2003-11-07 2004-11-05 Применение ингибиторов глюкозидазы для терапии муковисцидоза
NZ547261A NZ547261A (en) 2003-11-07 2004-11-05 Use of glucosidase inhibitors for therapy of mucovisidosis
JP2006538890A JP4740868B2 (ja) 2003-11-07 2004-11-05 膵線維症の治療のためのグルコシダーゼ阻害剤の使用
US10/578,328 US7973054B2 (en) 2003-11-07 2004-11-05 Use of glucosidase inhibitors for therapy of mucovisidosis
ZA200603726A ZA200603726B (en) 2003-11-07 2004-11-05 Use of glucosidase inhibitors for therapy of mucovisidosis
KR1020107004147A KR20100038452A (ko) 2003-11-07 2004-11-05 글루코시다제 억제제를 포함하는 낭성 섬유증 치료용 약제학적 조성물
KR1020067010948A KR100979276B1 (ko) 2003-11-07 2004-11-05 글루코시다제 억제제를 포함하는 낭성 섬유증 치료용 약제학적 조성물
SI200431106T SI1680105T1 (sl) 2003-11-07 2004-11-05 Uporaba inhibitorjev glukozidaze za zdravljenje mukoviscidoze
PCT/FR2004/002858 WO2005046672A2 (fr) 2003-11-07 2004-11-05 Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
CNB2004800382212A CN100534432C (zh) 2003-11-07 2004-11-05 葡糖苷酶抑制剂在粘液粘稠病治疗中的应用
ES04805405T ES2321725T3 (es) 2003-11-07 2004-11-05 Utilizacion de inhibidores de glucosidasa para un tratamiento de la mucoviscidosis.
PL04805405T PL1680105T3 (pl) 2003-11-07 2004-11-05 Zastosowanie inhibitorów glukozydazy do leczenia mukowiscydozy
EP04805405A EP1680105B1 (fr) 2003-11-07 2004-11-05 Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
CA2545133A CA2545133C (fr) 2003-11-07 2004-11-05 Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
PT04805405T PT1680105E (pt) 2003-11-07 2004-11-05 Utilização de inibidores de glucosidase para o tratamento de mucoviscidose
IL175453A IL175453A (en) 2003-11-07 2006-05-04 Use of glucosidase inhibitor, 1-butyl,2-hydroxymethyl-piperidine-3alpha,4beta,5-triol, for the preparation of a medicament for therapy of mucoviscidosis
NO20062617A NO336904B1 (no) 2003-11-07 2006-06-07 Anvendelse av glukosidaseinhibitorer for fremstilling av medikamenter for behandling av mukovisidose
CY20091100518T CY1110468T1 (el) 2003-11-07 2009-05-14 Χρηση αναστολεων γλυκοσιδασης για μια θεραπεια της κυστικης ινωσεως
US13/116,482 US8242136B2 (en) 2003-11-07 2011-05-26 Use of glucosidase inhibitors for therapy of mucovisidosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0313134A FR2861991B1 (fr) 2003-11-07 2003-11-07 Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose

Publications (2)

Publication Number Publication Date
FR2861991A1 FR2861991A1 (fr) 2005-05-13
FR2861991B1 true FR2861991B1 (fr) 2008-01-18

Family

ID=34508347

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0313134A Expired - Fee Related FR2861991B1 (fr) 2003-11-07 2003-11-07 Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose

Country Status (24)

Country Link
US (2) US7973054B2 (fr)
EP (1) EP1680105B1 (fr)
JP (1) JP4740868B2 (fr)
KR (2) KR100979276B1 (fr)
CN (1) CN100534432C (fr)
AT (1) ATE423561T1 (fr)
AU (1) AU2004289083B2 (fr)
BR (1) BRPI0416228A (fr)
CA (1) CA2545133C (fr)
CY (1) CY1110468T1 (fr)
DE (1) DE602004019674D1 (fr)
DK (1) DK1680105T3 (fr)
ES (1) ES2321725T3 (fr)
FR (1) FR2861991B1 (fr)
HR (1) HRP20090159T1 (fr)
IL (1) IL175453A (fr)
NO (1) NO336904B1 (fr)
NZ (1) NZ547261A (fr)
PL (1) PL1680105T3 (fr)
PT (1) PT1680105E (fr)
RU (1) RU2358725C2 (fr)
SI (1) SI1680105T1 (fr)
WO (1) WO2005046672A2 (fr)
ZA (1) ZA200603726B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572148T3 (es) 2005-05-17 2016-05-30 Amicus Therapeutics Inc Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
US8410081B2 (en) * 2006-04-24 2013-04-02 Academisch Medisch Centrum Treatment of cystic fibrosis
HUE027569T2 (en) 2006-05-16 2016-10-28 Amicus Therapeutics Inc Preparation for the treatment of Fabry disease
EP2352828B1 (fr) * 2008-09-11 2015-02-25 Galapagos N.V. Procédé d'identification de composés pour augmenter l'activité de mutant de cystic fibrosis transmembrane conductance regulator (cftr) associé à cf
ITFE20080032A1 (it) * 2008-10-23 2010-04-24 Azienda Ospedaliera Istituti Ospit Alieri Di Vero Effetto anti infiammatorio del miglustat cellule dell'epitelio bronchiale
GB201000499D0 (en) 2010-01-13 2010-03-03 Fleet George W J Treatment of cystic fibrosis
WO2011095772A2 (fr) 2010-02-04 2011-08-11 Summit Corporation Plc Nouveaux agents thérapeutiques iminosucres
GB201006434D0 (en) * 2010-04-19 2010-06-02 Summit Corp Plc Novel iminosugar combinations
KR20230066482A (ko) 2012-03-07 2023-05-15 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
HK1222129A1 (zh) * 2013-09-16 2017-06-23 Emergent Virology Llc 脱氧野尻霉素衍生物及其使用方法
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
EA038986B1 (ru) 2014-09-30 2021-11-18 Амикус Терапьютикс, Инк. Высокоактивная кислая альфа-глюкозидаза с повышенным содержанием углеводов
KR20250007693A (ko) 2015-12-30 2025-01-14 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
KR102444612B1 (ko) 2016-03-30 2022-09-21 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
KR102790256B1 (ko) 2016-03-30 2025-04-04 아미쿠스 세라퓨틱스, 인코포레이티드 고 m6p 재조합 단백질의 선택 방법
EP3448410A1 (fr) * 2016-04-29 2019-03-06 Institut Pasteur Procédés et compositions destinés à modifier l'activité régulatrice de la conductance transmembranaire d'une fibrose kystique
US10478427B2 (en) * 2016-07-07 2019-11-19 National University Corporation Chiba University Therapeutic agent for fibrosis and inhibitor of nuclear translocation of phosphorylated smad
JP7193476B2 (ja) 2017-05-15 2022-12-20 アミカス セラピューティックス インコーポレイテッド 組換えヒト酸性アルファグリコシダーゼ
AU2018278247B2 (en) * 2017-06-01 2022-07-28 Idorsia Pharmaceuticals Ltd Crystalline form of N-butyldeoxygalactonojirimycin
CN108187051A (zh) * 2018-01-30 2018-06-22 中国药科大学 α-L-岩藻糖苷酶及抑制剂用于制备防治心肌缺血损伤的药物的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
CA2108584C (fr) * 1992-10-27 1998-11-24 James B. Doherty Utilisation d'azetidinones substituees comme anti-inflammatoires et agents anti-degeneratifs
WO1998020123A2 (fr) 1996-11-04 1998-05-14 Institut Curie Lignes cellulaires stables exprimant la proteine cftr ou un mutant de cette proteine, outil pour selectionner des molecules ayant un effet sur le transport intracellulaire desdites proteines
TW589174B (en) 1997-12-10 2004-06-01 Takeda Chemical Industries Ltd Agent for treating high-risk impaired glucose tolerance
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
WO2001002586A1 (fr) * 1999-06-29 2001-01-11 Mcgill University Alpha 1,2-mannosidase humaine
US6476194B1 (en) * 1999-06-29 2002-11-05 National Research Council Of Canada Method for folding unfolded proteins
AU7398900A (en) * 1999-09-23 2001-04-24 Hospital For Sick Children, The Three-dimensional structure and crystal of a class i alpha1,2-mannosidase, and methods of use thereof
US20050053625A1 (en) * 2001-10-30 2005-03-10 Block Timothy M Method of treating viral infections
US7081260B2 (en) 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
MX344587B (es) 2003-01-31 2016-12-20 Mount Sinai School Of Medicine Of New York Univ Metodo para incrementar la estabilidad in vitro e in vivo de enzimas asociadas al transtorno lisosomal.
US7071341B2 (en) 2003-02-28 2006-07-04 Council Of Scientific And Industrial Research α-Glucosidase inhibitors and their synthesis from a natural source

Also Published As

Publication number Publication date
RU2358725C2 (ru) 2009-06-20
NO20062617L (no) 2006-07-25
KR100979276B1 (ko) 2010-08-31
KR20100038452A (ko) 2010-04-14
ZA200603726B (en) 2007-12-27
ES2321725T3 (es) 2009-06-10
AU2004289083A1 (en) 2005-05-26
NO336904B1 (no) 2015-11-23
PL1680105T3 (pl) 2009-07-31
US20110269795A1 (en) 2011-11-03
US7973054B2 (en) 2011-07-05
JP4740868B2 (ja) 2011-08-03
SI1680105T1 (sl) 2009-08-31
PT1680105E (pt) 2009-05-20
JP2007510699A (ja) 2007-04-26
BRPI0416228A (pt) 2007-01-02
NZ547261A (en) 2009-11-27
WO2005046672A2 (fr) 2005-05-26
US8242136B2 (en) 2012-08-14
CY1110468T1 (el) 2015-04-29
FR2861991A1 (fr) 2005-05-13
AU2004289083B2 (en) 2009-12-03
DE602004019674D1 (de) 2009-04-09
CN100534432C (zh) 2009-09-02
IL175453A (en) 2012-09-24
CA2545133C (fr) 2013-04-16
CN1897933A (zh) 2007-01-17
EP1680105A2 (fr) 2006-07-19
CA2545133A1 (fr) 2005-05-26
IL175453A0 (en) 2008-03-20
WO2005046672A3 (fr) 2005-09-15
ATE423561T1 (de) 2009-03-15
US20070213357A1 (en) 2007-09-13
EP1680105B1 (fr) 2009-02-25
KR20060130058A (ko) 2006-12-18
DK1680105T3 (da) 2009-06-29
HRP20090159T1 (en) 2009-05-31
RU2006119914A (ru) 2007-12-20

Similar Documents

Publication Publication Date Title
FR2861991B1 (fr) Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
Ding et al. What is noise-induced hearing loss?
Bohm et al. In patients with out-of-hospital cardiac arrest, does the provision of dispatch cardiopulmonary resuscitation instructions as opposed to no instructions improve outcome: a systematic review of the literature
BR0308739A (pt) Tratamentos em combinação para doenças mediadas por quimiocina
NO20040968L (no) Opioidagonistpreparater med frigjorbar og sekvestrert antagonist
EP1587834A4 (fr) Utilisations de cytokine de mammifere et reactifs correspondants
EP1622663A4 (fr) Appareil et procede d'administration d'agents therapeutiques et/ou diagnostiques
EP1576110A4 (fr) Compositions inhibant la migration cellulaire et methodes et compositions pour le traitement du cancer
TR200001942T2 (tr) Opioid agonist/antagonist kombinasyonlar
DK1373470T3 (da) Hidtil ukendte substitutionsmutantreceptorer og deres anvendelse i et cellekernereceptorbaseret inducerbart genekspressionssystem
EP1499176A4 (fr) Nouvelles toxines vip3 et leurs procedes d'utilisation
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
AU2003277421A8 (en) Verification of identity and continued presence of computer users
NO20001401L (no) Ny anvendelse av budesonid og formoterol
TR200003787A2 (tr) Kararlı yavaş salımlı oral dozaj bileşimi.
UA88440C2 (ru) ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β
WO2006088956A3 (fr) Procedes de prediction de reponse therapeutiques dans la dermatite atopique aux antagonistes il-31
NO20055136D0 (no) Farmasoytisk sammensetning som innbeffatter et immunosuppressivt stoff for bruk ved behandling av hudsykdommer
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
ATE488250T1 (de) Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
EP1542664A4 (fr) Methodes et compositions de traitement de troubles maculaires et retinaux
AU1092602A (en) Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detectingthem and therapeutic method and remedies for rheumatoid arthritis
EP1562563A4 (fr) Methodes pour le traitement de maladies caracterisees par une deficience en composes contenant du thiol
WO2006017861A3 (fr) Traitement de l'accoutumance à la méthamphétamine et réduction de la prise de méthamphétamine au moyen d'antagonistes de la sérotonine
GB0201367D0 (en) Composition

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 17

ST Notification of lapse

Effective date: 20210705